Outcomes of patients with AML classified into different subgroups according to posttransplantation MRD using different biomarkers (n = 360)
| . | 2-y CIR . | 2-y NRM . | 2-y LFS . | 2-y OS . |
|---|---|---|---|---|
| Total patients (n = 360) | ||||
| Cases with negative CD34+CD38−cocktail+ LSC | 3.8% | 7.2% | 89.0% | 89.6% |
| (n = 312, group A) | (95% CI, 1.3%-6.3%) | (95% CI, 3.9%-10.5%) | (95% CI, 85.1%-92.9%) | (95% CI, 85.9%-93.9%) |
| Cases with positive CD34+CD38−cocktail+ LSC | 44.3%* | 2.1% | 53.5%* | 62.3%* |
| (n = 48, group B) | (95% CI, 29.2%-59.4%)* | (95% CI, 0%-6.4%) | (95% CI, 38.6%-68.4%)* | (95% CI, 46.8%-77.8%)* |
| Total patients (n = 360) | ||||
| Cases with negative CD34+CD38−cocktail+/CD33+/CD45RA+ LSC† | 2.5% | 6.8% | 90.9% | 92.1% |
| (n = 254, group C) | (95% CI, 0.1%-4.9%) | (95% CI, 3.7%-9.9%) | (95% CI, 87.2%-94.6%) | (95% CI, 88.8%-95.4%) |
| Cases with positive CD34+CD38−cocktail+/CD33+/CD45RA+ LSC | 26.2%‡ | 7.3% | 68.1%‡ | 77.4%‡ |
| (n = 106, group D) | (95% CI, 17.2%-35.2%)‡ | (95% CI, 1.4%-13.2%) | (95% CI, 58.5%-77.7%)‡ | (95% CI, 69.0%-85.8%)‡ |
| Total patients (n = 360) | ||||
| Cases with negative traditional MRD determined by MFC | 7.3% | 7.2% | 85.6% | 87.5% |
| (n = 327, group E) | (95% CI, 3.6%-11.0%) | (95% CI, 4.1%-10.3%) | (95% CI, 80.9%-90.3%) | (95% CI, 82.6%-92.4%) |
| Cases with positive traditional MRD determined by MFC | 44.9%‖ | 0% | 55.1%‖ | 55.6%‖ |
| (n = 33, group F) | (95% CI, 25.1%-64.7%)‖ | (95% CI, 35.9%-74.3%)‖ | (95% CI, 35.2%-76.0%)‖ |
| . | 2-y CIR . | 2-y NRM . | 2-y LFS . | 2-y OS . |
|---|---|---|---|---|
| Total patients (n = 360) | ||||
| Cases with negative CD34+CD38−cocktail+ LSC | 3.8% | 7.2% | 89.0% | 89.6% |
| (n = 312, group A) | (95% CI, 1.3%-6.3%) | (95% CI, 3.9%-10.5%) | (95% CI, 85.1%-92.9%) | (95% CI, 85.9%-93.9%) |
| Cases with positive CD34+CD38−cocktail+ LSC | 44.3%* | 2.1% | 53.5%* | 62.3%* |
| (n = 48, group B) | (95% CI, 29.2%-59.4%)* | (95% CI, 0%-6.4%) | (95% CI, 38.6%-68.4%)* | (95% CI, 46.8%-77.8%)* |
| Total patients (n = 360) | ||||
| Cases with negative CD34+CD38−cocktail+/CD33+/CD45RA+ LSC† | 2.5% | 6.8% | 90.9% | 92.1% |
| (n = 254, group C) | (95% CI, 0.1%-4.9%) | (95% CI, 3.7%-9.9%) | (95% CI, 87.2%-94.6%) | (95% CI, 88.8%-95.4%) |
| Cases with positive CD34+CD38−cocktail+/CD33+/CD45RA+ LSC | 26.2%‡ | 7.3% | 68.1%‡ | 77.4%‡ |
| (n = 106, group D) | (95% CI, 17.2%-35.2%)‡ | (95% CI, 1.4%-13.2%) | (95% CI, 58.5%-77.7%)‡ | (95% CI, 69.0%-85.8%)‡ |
| Total patients (n = 360) | ||||
| Cases with negative traditional MRD determined by MFC | 7.3% | 7.2% | 85.6% | 87.5% |
| (n = 327, group E) | (95% CI, 3.6%-11.0%) | (95% CI, 4.1%-10.3%) | (95% CI, 80.9%-90.3%) | (95% CI, 82.6%-92.4%) |
| Cases with positive traditional MRD determined by MFC | 44.9%‖ | 0% | 55.1%‖ | 55.6%‖ |
| (n = 33, group F) | (95% CI, 25.1%-64.7%)‖ | (95% CI, 35.9%-74.3%)‖ | (95% CI, 35.2%-76.0%)‖ |
CI, confidence interval; NRM, nonrelapse mortality.
P < .001 compared with group A.
The LSC-based MRD positivity was defined as patients with either CD34+CD38−cocktail+ LSC ≥ 0.004%, or CD34+CD38−CD33+ LSC ≥ 0.025%, or CD34+CD38−CD45RA+ LSC ≥ 0.007%.
P < .01 compared with group C.
P < .001 compared with group E.